These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34357560)

  • 1. Effectiveness of IGlarLixi, a Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide, in People with Type 2 Diabetes.
    Kis JT; Nagy G; Kovacs G
    Diabetes Ther; 2021 Sep; 12(9):2517-2529. PubMed ID: 34357560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world evidence on the use of a fixed-ratio combination of insulin glargine and lixisenatide (iGlarLixi) in people with suboptimally controlled type 2 diabetes in Romania: a prospective cohort study (STAR.Ro).
    Bala C; Cerghizan A; Mihai BM; Moise M; Guja C
    BMJ Open; 2022 May; 12(5):e060852. PubMed ID: 35623748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of iGlarLixi for the Management of Type 2 Diabetes in Japanese Clinical Practice: Prior Treatment Subgroup Analysis of the SPARTA Japan Study.
    Miyoshi H; Matsuhisa M; Yabe D; Takahashi Y; Morimoto Y; Terauchi Y
    Diabetes Ther; 2023 Apr; 14(4):671-689. PubMed ID: 36809494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study.
    Matsuhisa M; Miyoshi H; Yabe D; Takahashi Y; Morimoto Y; Terauchi Y
    Diabetes Ther; 2023 Jan; 14(1):219-236. PubMed ID: 36422802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Participant Characteristics on Clinical Outcomes with iGlarLixi in Type 2 Diabetes: Post Hoc Analysis of SPARTA Japan.
    Yabe D; Matsuhisa M; Takahashi Y; Morimoto Y; Terauchi Y
    Diabetes Ther; 2024 Mar; 15(3):705-723. PubMed ID: 38363541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.
    Goldman J; Trujillo JM
    Ann Pharmacother; 2017 Nov; 51(11):990-999. PubMed ID: 28645216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicentre study: The LixiLan JP-O2 randomized clinical trial.
    Terauchi Y; Nakama T; Spranger R; Amano A; Inoue T; Niemoeller E
    Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():14-23. PubMed ID: 32291880
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and Safety of iGlarLixi in People with Type 2 Diabetes in Adriatic Region Countries: ENSURE-ADR, a Real-World Study.
    Đekić D; Bojić M; Janež A; Klobučar S; Hadžimušović IG; Ković T; Mihalevska S
    Diabetes Ther; 2023 Jul; 14(7):1217-1229. PubMed ID: 37211579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concomitant iGlarLixi and Sodium-Glucose Co-transporter-2 Inhibitor Therapy in Adults with Type 2 Diabetes: LixiLan-G Trial and Real-World Evidence Results.
    Guja C; Giorgino F; Blonde L; Ali A; Prázný M; Meier JJ; Souhami E; Lubwama R; Ji C; Rosenstock J
    Diabetes Ther; 2022 Jan; 13(1):205-215. PubMed ID: 34894329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data.
    Guja C; Kis JT; Haluzík M; Bonnemaire M; Bigot G; Tournay M; Freemantle N; Seufert J
    Diabetes Obes Metab; 2023 Jun; 25(6):1723-1730. PubMed ID: 36810874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EFFICACY AND SAFETY OF IGLARLIXI IN HISPANICS AND NON-HISPANIC WHITES WITH TYPE 2 DIABETES.
    Mora PF; Chao J; Saremi A; Dex TA; Roberts M; Umpierrez GE
    Endocr Pract; 2019 Nov; 25(11):1091-1100. PubMed ID: 31241362
    [No Abstract]   [Full Text] [Related]  

  • 12. Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
    Rosenstock J; Blonde L; Aroda VR; Frias J; Souhami E; Ji C; Niemoeller E; Del Prato S
    Diabetes Obes Metab; 2021 Jun; 23(6):1331-1341. PubMed ID: 33565209
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of a single dose of insulin glargine/lixisenatide fixed ratio combination (iGlarLixi) on postprandial glucodynamic response in Japanese patients with type 2 diabetes mellitus: A phase I randomized trial.
    Inoue M; Lorenz M; Muto H; Wesch R; Hashimoto Y
    Diabetes Obes Metab; 2019 Aug; 21(8):2001-2005. PubMed ID: 31050109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits of the fixed-ratio combination of insulin glargine 100 units/mL and lixisenatide (iGlarLixi) in Japanese people with type 2 diabetes: A subgroup and time-to-control analysis of the LixiLan JP phase 3 trials.
    Terauchi Y; Yabe D; Kaneto H; Amano A; Baxter M; Watanabe D; Watada H; Inagaki N
    Diabetes Obes Metab; 2020 Sep; 22 Suppl 4():35-47. PubMed ID: 33404200
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial.
    Rosenstock J; Emral R; Sauque-Reyna L; Mohan V; Trescolí C; Al Sifri S; Lalic N; Alvarez A; Picard P; Bonnemaire M; Demil N; McCrimmon RJ;
    Diabetes Care; 2021 Jun; 44(10):2361-70. PubMed ID: 34183429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The IDEAL (Insulin therapy DE-intensificAtion with iglarLixi) Randomised Controlled Trial-Study Design and Protocol.
    Novodvorský P; Thieme L; Laňková I; Mráz M; Taybani ZJ; Bótyik B; Stella P; Vytasil M; Lauand F; Bonnemaire M; Haluzík M
    Diabetes Ther; 2024 Jun; 15(6):1461-1471. PubMed ID: 38653903
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness, Safety, and Appropriateness in the Use of the Fixed-Ratio Combination of Insulin Glargine and Lixisenatide in Type 2 Diabetes: The ENSURE Retrospective Real-World Study.
    Candido R; Modugno M; Larosa M; Rossi MC; Nicolucci A; Gabellieri E;
    Diabetes Ther; 2023 Jan; 14(1):77-92. PubMed ID: 36376644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ease of Use of the iGlarLixi SoloStar Pen from the LixiLan ONE CAN Pen Sub-Study: Questionnaire Findings from People Living with Type 2 Diabetes and Their HealthCare Providers.
    Yale JF; Roborel de Climens A; Aggarwal N; Dex T; Gerstein HC; Harris S; Hramiak I; Stewart J; Leiter LA
    Diabetes Ther; 2023 Feb; 14(2):377-386. PubMed ID: 36574199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of iGlarLixi, Fixed-Ratio Combination of Insulin Glargine and Lixisenatide, Compared with Basal-Bolus Regimen in Patients with Type 2 Diabetes: Propensity Score Matched Analysis.
    Tabák ÁG; Anderson J; Aschner P; Liu M; Saremi A; Stella P; Tinahones FJ; Wysham C; Meier JJ
    Diabetes Ther; 2020 Jan; 11(1):305-318. PubMed ID: 31848983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and Safety of iGlarLixi (Insulin Glargine 100 U/mL Plus Lixisenatide) in Type 2 Diabetes According to the Timing of Daily Administration: Data from the REALI Pooled Analysis.
    Haluzík M; Seufert J; Guja C; Bonnemaire M; Bigot G; Tournay M; Kis JT; Freemantle N
    Diabetes Ther; 2023 Apr; 14(4):639-652. PubMed ID: 36787044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.